Literature DB >> 15011248

MRI detects early hindlimb muscle atrophy in Gly93Ala superoxide dismutase-1 (G93A SOD1) transgenic mice, an animal model of familial amyotrophic lateral sclerosis.

Keith J Brooks1, Mark D W Hill, Paul D Hockings, David G Reid.   

Abstract

MRI has been used to measure hindlimb muscle volume in female and male transgenic mice overexpressing the Gly93Ala (G93A) mutant human superoxide dismutase 1 (SOD1), a widely used model of familial amyotrophic lateral sclerosis (FALS), over the first 4 months of life. Significant decreases in the hindlimb muscle volume of the female G93A SOD1 mice were evident from 11 weeks of age, before other overt pathology appeared. By 15 weeks volume had decreased by 37% compared with 7 weeks, from 0.84+/-0.04 cm(3) (mean+/-standard deviation, n = 6) to 0.54+/-0.07 cm(3), (p < 0.05), despite an increase in body weight of ca. 12% (from 16.2 +/- 1.4 to 18.1 +/- 0.7 g). Female wild-type volume increased by ca. 30% whilst the body weight increased by 15%. Muscle wasteage was less (0.82+/-0.1 to 0.65+/-0.02 cm(3), p < 0.05, n = 6) in male G93A SOD1 mice between 8 and 16 weeks of age, against a body weight increase trend from 20.7 +/- 0.4 to 21.6 +/- 0.5 g, (p > 0.05). Wild-type male muscle volume did not change significantly over this period, with an increase in body weight of 20%. Longitudinal MRI hindlimb muscle volume measurements may provide a straightforward, rapid, non-invasive and sensitive, way of monitoring outcome of experimental ALS treatments. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15011248     DOI: 10.1002/nbm.861

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  12 in total

1.  Quantity and activation of myofiber-associated satellite cells in a mouse model of amyotrophic lateral sclerosis.

Authors:  Raquel Manzano; Janne M Toivonen; Ana Cristina Calvo; Sara Oliván; Pilar Zaragoza; Maria Jesús Muñoz; Didier Montarras; Rosario Osta
Journal:  Stem Cell Rev Rep       Date:  2012-03       Impact factor: 5.739

Review 2.  Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis.

Authors:  Seward B Rutkove
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 3.  Mechanisms of Muscle Denervation in Aging: Insights from a Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Kevin H J Park
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 4.  Neurodegenerative diseases: model organisms, pathology and autophagy.

Authors:  S N Suresh; Vijaya Verma; Shruthi Sateesh; James P Clement; Ravi Manjithaya
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

5.  Monitoring systemic oxidative stress in an animal model of amyotrophic lateral sclerosis.

Authors:  Francisco Javier Miana-Mena; Cristina González-Mingot; Pilar Larrodé; María Jesús Muñoz; Sara Oliván; Lorena Fuentes-Broto; Enrique Martínez-Ballarín; Russel J Reiter; Rosario Osta; Joaquín José García
Journal:  J Neurol       Date:  2010-11-25       Impact factor: 4.849

6.  Optimised and rapid pre-clinical screening in the SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS).

Authors:  Richard J Mead; Ellen J Bennett; Aneurin J Kennerley; Paul Sharp; Claire Sunyach; Paul Kasher; Jason Berwick; Brigitte Pettmann; Guiseppe Battaglia; Mimoun Azzouz; Andrew Grierson; Pamela J Shaw
Journal:  PLoS One       Date:  2011-08-18       Impact factor: 3.240

7.  Neuromuscular junction protection for the potential treatment of amyotrophic lateral sclerosis.

Authors:  Dan Krakora; Corey Macrander; Masatoshi Suzuki
Journal:  Neurol Res Int       Date:  2012-08-07

8.  Transcriptome Profiling Following Neuronal and Glial Expression of ALS-Linked SOD1 in Drosophila.

Authors:  Emily L Kumimoto; Taylor R Fore; Bing Zhang
Journal:  G3 (Bethesda)       Date:  2013-04-09       Impact factor: 3.154

9.  Hypophosphatemia promotes lower rates of muscle ATP synthesis.

Authors:  Dominik H Pesta; Dimitrios N Tsirigotis; Douglas E Befroy; Daniel Caballero; Michael J Jurczak; Yasmeen Rahimi; Gary W Cline; Sylvie Dufour; Andreas L Birkenfeld; Douglas L Rothman; Thomas O Carpenter; Karl Insogna; Kitt Falk Petersen; Clemens Bergwitz; Gerald I Shulman
Journal:  FASEB J       Date:  2016-06-23       Impact factor: 5.191

10.  Long-term interleukin-33 treatment delays disease onset and alleviates astrocytic activation in a transgenic mouse model of amyotrophic lateral sclerosis.

Authors:  Paula Korhonen; Eveliina Pollari; Katja M Kanninen; Ekaterina Savchenko; Šárka Lehtonen; Sara Wojciechowski; Yuriy Pomeshchik; Ludo Van Den Bosch; Gundars Goldsteins; Jari Koistinaho; Tarja Malm
Journal:  IBRO Rep       Date:  2019-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.